CWC
SAGE icon

Carolinas Wealth Consulting’s Sage Therapeutics SAGE Stock Holding History

Carolinas Wealth Consulting’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6
Closed – – 1010
2020
Q3 		$0 Hold
6
– – ﹤0.01% 995
2020
Q2 		$0 Buy
+6
New +$218 ﹤0.01% 715

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Carolinas Wealth Consulting's SAGE Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 6 shares.

Carolinas Wealth Consulting first reported a position in SAGE in Q2 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2020. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 6 Sage Therapeutics shares in Q4 2020.
  • Carolinas Wealth Consulting first reported a position in Sage Therapeutics in Q2 2020 and held it in 2 quarters.
  • Carolinas Wealth Consulting's Sage Therapeutics position peaked at $0 in Q3 2020.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.